



Unlocking the Potential of Cannabinoid Medicines

Exchange:	TSX: IN	OTCQX: IMLFF
Share Price (01/02/19):	C\$0.38	US\$0.28
Market Capitalization (01/02/19):	C\$65.8M	US\$49.9M

Company Highlights

InMed is a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs.

Exploring the potential of all 90+ cannabinoid compounds, not just THC & CBD	Selects specific cannabinoids (or combinations) with high potential to play a role in regulating specific diseases	Biosynthesizes cannabinoids that are biologically identical to those produced by the plant itself	Develops innovative, topically applied therapies for diseases with high unmet medical need
--	--	---	--

Cannabinoids

Beyond the two most well-known cannabinoids THC and CBD, the human body's endocannabinoid receptors are predisposed to interact with more than 90 other cannabinoids that have potential therapeutic properties. Many of these cannabinoids have been neglected as targets of scientific research because they are found in extremely low concentrations in the cannabis plant.


InMed is developing novel, non-THC, topically applied cannabinoid-based treatments for diseases with high unmet medical needs.

Biosynthesis

Proprietary biosynthesis program will allow InMed, and potentially other companies through commercial partnerships, to access cannabinoids that are found in very limited amounts in the plant. These cannabinoids (i.e. "minor cannabinoids") may hold significant potential to treat human diseases.

This potentially industry-disruptive cannabinoid manufacturing process may offer several advantages over traditional methods (extraction from plants and chemical synthesis), which include:

Significant cost & time savings vs existing growing / harvesting / extraction / purification methods	Access to minor cannabinoids that are currently economically unfeasible via plant extraction	Enhanced production, purification and quality control vs naturally-sourced products	Increased structural integrity vs chemical manufacturing methods
--	--	---	--



Clinical Pipeline

	INM-750	INM-085	INM-405
Therapeutic Area	Epidermolysis Bullosa	Glaucoma	Orofacial Pain
Addressable Market	10.1K	14.2M	52.7M
Market Potential	\$1.0B	\$5.6B	\$4.0B

Strong Intellectual Property Strategy

Filed several **Patent Cooperation Treaty (PCT) and provisional patent applications** to protect our inventions. Recent **PCT patent applications** include:

-  **Sept. 25, 2018:** INM-405 program and other unique compositions as cannabinoid-based topical therapies for the treatment of pain
-  **Sept. 10, 2018:** Proprietary biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature
-  **May 14, 2018:** INM-085, a cannabinoid-based topical therapy for glaucoma
-  **Mar. 2, 2017:** INM-750 as a cannabinoid-based topical therapy for Epidermolysis Bullosa Simplex
-  **May 4, 2017:** Cannabinoid-Based Topical Therapy for Diseases and Conditions Associated with Intermediate Filament Dysfunction

InMed expects to continue to protect its intellectual property via additional patent filings in the coming months and on an on-going basis.

INM-750 Epidermolysis Bullosa (EB)

- Group of genetic conditions causing skin to be very fragile and blister / rupture easily in response to minor injury or friction, such as rubbing or scratching
- INM-750 being investigated to deliver symptomatic relief in all EB patients via multiple potential mechanisms of action:
 - ✓ accelerated wound healing
 - ✓ pain reduction
 - ✓ itch reduction
 - ✓ reduce inflammation
 - ✓ antimicrobial activity
- May re-establish the epidermal / dermal junction by upregulation of specific keratins in the skin, potentially reversing the disease in a subset of EB patients


INM-085 Glaucoma

Dual Mechanism of Action

- ✓ Reduces the intraocular pressure (IOP) in the affected eyes
- ✓ Provide neuroprotection for the retinal ganglion cells (RGCs) and other optic nerve tissues in the affected eyes

Proprietary Delivery System

- ✓ INM-085 utilizes a 1x per day hydrogel to improve compliance
- ✓ Preclinical animal data showed enhanced penetration of cannabinoid molecules through the cornea and lens compared to control



Recent News

Dec. 4, 2018

- ✓ Received funding from the Government of Canada to support development of novel cannabinoid biosynthesis program

Nov. 5, 2018

- ✓ Appointed Michael Woudenberg as Vice President, Chemistry, Manufacturing and Controls

Oct. 3, 2018

- ✓ Signed agreement with the National Research Council of Canada for cannabinoid biofermentation process development and scale-up

Sept. 25, 2018

- ✓ Filed PCT patent application for INM-405 and other treatments of pain with cannabinoids

Sept. 11, 2018

- ✓ NSERC grant directed University of British Columbia in support of InMed's collaborative R&D work

Development Targets

- INM-750**
 - 1H19: Pre-IND meeting
 - 2H19: IND filing
 - 2H19: Initiate Phase 1 clinical trials
- INM-085**
 - 2H18: Conduct additional *in vitro* analyses ✓
 - 1H19: Initiate additional preclinical *in vivo* studies
 - 1H19: Conduct additional formulation optimization

Management Team

Eric A. Adams, MIBS

Chief Executive Officer

30+ years experience in global biopharma leadership: business development, sales, marketing, M&A with enGene, QLT, Abbott, Fresenius.

Jeff Charpentier, CPA, CA

Chief Financial Officer

25+ years experience in biotech and tech companies, including Lifebank Corp., Inex Pharmaceuticals, and Chromos Molecular Systems.

Josh Blacher, MBA

Chief Business Officer

20+ years of senior leadership, capital markets experience with Therapix, Galmed, Teva and investment banking with Morgan Stanley, and Lehman Bros.

Sazzad Hossain, PhD, MSc

CSO, Co-Founder

20+ years of academic/industry experience in drug discovery and development; Xenon Pharma and Canada's National Research Council

Alexandra D.J. Mancini, MSc

SVP, Clinical and Regulatory Affairs

30+ years' global biopharmaceutical R&D experience with numerous biotech companies, including Sirius Genomics, INMEX Pharmaceuticals, and QLT Inc.

Dr. Eric C. Hsu, PhD

VP, Preclinical R&D

18+ years of scientific leadership experience with enGene Inc. in novel gene transfer technologies, formulation development and process development

Investor Relations Contacts

Josh Blacher
InMed Pharma, CBO
(778) 945-0960
jblacher@inmedpharma.com

Joe Green
Edison Advisors
(646) 653-7035
jgreen@edisongroup.com

Financials

TSX: IN (as at 01/02/2019)
Shares Outstanding 170.9M
Options/Warrants 50.5M
Fully Diluted 221.4M
Cash/Cash Equivalents on Hand (at 9/30/18) C\$24.8M